1. Pink Sheet
  2. >>Geography
  3. >>Europe

What You Need To Know About Liability Protection For COVID-19 Products

Companies developing medical countermeasures for COVID-19 need to become familiar with divergences in the liability protection offered by different countries with regard to possible safety issues that may arise when products are fast-tracked for public health reasons. By doing so they can adopt a systematic process for prospectively evaluating and managing international risks, say Dan Kracov, Lincoln Tsang and Alexander Roussanov.

Liability
Liability should be a key concern for developers of COVID-19 products • Source: Shutterstock

The COVID-19 pandemic has brought unprecedented challenges. The rapid cross-border spread of the virus has prompted the international regulatory community to work closely together. For this reason, a consistent international approach has rightly been adopted towards collecting robust and reliable evidence to establish the safety and efficacy of medical countermeasures for COVID-19.

About The Authors

Dan Kracov, Lincoln Tsang and Alexander Roussanov are partners in, respectively, the Washington, DC, London and

While the intention of the regulators is to hold such products to the usual high standards and ensure they have a favorable benefit-risk profile, the urgent need for cures and vaccines means they need to be made available within a relatively short period of time

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Brazil To Upgrade Pricing Framework To Keep Up With Market Developments

 
• By Francesca Bruce

Brazil plans to clarify its medicine pricing framework, for example by outlining the procedures for setting medicine prices and bring it up to date with recent developments in the sector.

England: HTA Sandbox Helping To Assess ‘Challenging’ Drugs And Indications

 
• By Eliza Slawther

England’s health technology assessment institute explains how its sandbox environment is helping to test new evaluation methods for drugs or indications with which it does not have experience, such as metabolic dysfunction-associated steatohepatitis.

Unlocking Opportunities: How To Engage With The EMA On Animal Testing Alternatives

 
• By Neena Brizmohun

The European Medicines Agency, like its counterpart in the US, is increasingly focusing on the use of alternatives to animal testing.